This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Containment Remove Contamination Remove Reagent Remove Vaccine
article thumbnail

Early phase support for plasmid DNA supply to secure future manufacturing

Drug Discovery World

JANUARY 19, 2023

pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines. Plasmid DNA: a critical reagent pDNA is the starting material for the development of many cell and gene therapy products, irrespective of the mode of action. coli cell bank that contains the plasmid.

DNA 52
DNA Manufacturing Gene Therapy Gene 52
article thumbnail

Optimising AAV capsid purification through improved analytics

Drug Discovery World

FEBRUARY 8, 2023

Partially-filled capsids may also be present, and contain packaged process-related impurities or truncated genetic material. During AAV process development, there are numerous variables that need to be optimised to maximise the number of full capsids while minimising contaminants. Benchmarking mass photometry against cryoTEM and AUC.

Gene Therapy 52
Gene Therapy Gene Antibody Production 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024